P
PellePharm
PellePharm, Inc operates in the biotechnology industry
About PellePharm
PellePharm is a biotechnology company that focuses on developing treatments for rare dermatological diseases, specifically Gorlin Syndrome and Basal Cell Carcinomas (BCCs). The company operates in the biopharmaceutical market and primarily serves patients suffering from these conditions. PellePharm's core product is patidegib, an investigational topical treatment aimed at reducing the tumor burden in patients with Gorlin Syndrome and BCCs. The company collaborates with organizations like the Gorlin Syndrome Alliance, The Gorlin Syndrome Group, and LEO Pharma to advance its research and development efforts.
PellePharm's business model revolves around the development and eventual commercialization of patidegib. The company aims to generate revenue through the sale of this treatment once it receives regulatory approval. Currently, there are no FDA-approved drugs for Gorlin Syndrome, making surgery the standard of care. PellePharm's innovative approach targets the underlying genetic defects, offering a potentially transformative solution for patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Menlo Park, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 58.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2018 | $70M | $280M | LEO pharma | — |
| DEBTDebt | Jun 2018 | $7.5M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for PellePharm is 310 monthly website visits, down 56.3% over the last three months. PellePharm's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BridgeBio
Series B and later1 investor entered at this stage
LEO pharma
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PellePharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PellePharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.